Northwest Biotherapeutics Inc (QB) (NWBO) Cotización

zero82,

And you don’t think that commercialization would have any impact on the value of a pre-commercial clinical stage company?




https://investorshub.advfn.com/boards/read_msg.aspx?message_id=175564505

Doesn’t give anyone the reason to lie to shareholders. Lost over 60% value from that point on.

LP loves such bag holders!

Well they didn't specify revenue to whom

It is fascinating even to picture which company could be the one that LP selected among many parties which have considerable interest in providing complementary technologies. For biotech, would a company show considerable interest in something without knowing it or without careful due diligence about it? I assume that LP must have shown all these parties the data first and then they have considerable interest in collaboration. I should not say collaboration since their technologies are complementary. I automatically think of DCVax-L as DCVax-L in combination with Poly-ICLC by default. The tumor-agnostic combination trial carries tremendous significance. LP must have 100% certainty that it is going to be a successful one. LP must be certain that tumor shrinkage should happen within months. Would LP try PDL inhibitor from Roche? I don't see any research on this combination. How about PD1 inhibitor from BMS? UCLA did have four or five years of research on the combination of DCVax-L + Opdivo + PLX3397. But not human trial on the combination of DCVax-L + Opdivo. Still risky to start this combination as the first one. It is exciting that the longs will know the answer in three months.

For those who think that the vaccine facilities have something to do with Merck's approved vaccines currently available on the market, I really doubt it. IMO, most likely you are wrong.

Collaborations: Complementary or Synergistic Technologies. The Company has also been pursuing ongoing efforts to identify and develop collaborations with other companies who have technologies that the Company believes may be complementary to the Company’s DCVax technologies (for example for combination treatment regimens) or may be synergistic with the Company’s technologies (for example, to enhance DCVax products). The Company completed negotiations and entered into a contract with a company that has a complementary immunotherapy agent, and the two companies have been engaged for a number of months in joint development of trial designs and selection of candidate cancers for a combination treatment clinical trial. The companies are particularly focusing on trial designs in which the primary endpoint will be tumor response (shrinkage), with potential timeframes in months, rather than time-to-event survival outcomes, with timeframes in years. The Company anticipates potentially being ready to submit an IND for such a combination trial to regulators during Q1 of next year.

building 50 live virus vaccine filling facility project



https://www.merck.com/news/expansion-of-elkton-virginia-manufacturing-facility-to-further-increase-mercks-hpv-vaccine-supply-and-support-broader-and-equitable-access/


Merck, nearing completion of $1B Gardasil manufacturing push, eyes 2023 to double production?—again
https://www.fiercepharma.com/pharma/merck-amid-1b-plus-manufacturing-upgrade-adds-150-jobs-support-beefed-hpv-shot-production

The Gardasil maker has expanded human papillomavirus (HPV) vaccine capacity at its facility in Elkton, Virginia, to the tune of 120,000 square feet and 150 new jobs, Merck said Monday.

https://www.merck.com/news/merck-to-construct-new-facility-in-the-united-states-to-expand-manufacturing-capacity-for-tice-bcg/

The new facility will be part of the existing Maurice R. Hilleman Center for Vaccine Manufacturing in Durham, North Carolina. The facility is expected to create about 100 new jobs locally.  The Durham plant is part of Merck’s global and U.S. manufacturing network. Merck has continued to invest in its global manufacturing network as part of its planned capital investments of more than $20 billion from 2019 through the end of 2023.

https://www.builtinnyc.com/job/specialist-manufacturing-automation/271626

https://www.builtinnyc.com/job/specialist-operations-1st-shift/272530

https://www.themuse.com/jobs/merck/senior-specialist-engineering-technical-operations-vaccine-manufacturing

https://www.blackcareernetwork.com/job/senior-operations-specialist-facilities-and-project-lead-196638

https://jobs.merck.com/us/en/job/R328302/Senior-Scientist-Engineering

zero82,

Thanks for reminding us about compassionate use. You really are highlighting an excellent point with respect to the VALUE of the Specials Program! 😉




The greatest value of the compassionate use program extends well beyond any “revenue” and we do have the management to thank for running a successful program. The Specials Program fits beautifully into the big-picture strategy to achieve broader commercialization…

The same MHRA regulators who have been supporting the long-running and ongoing UK Specials Program may also consider its data as part of their review if those data are included in the voluminous MAA package.

Regulators may also choose to consider any analyses that are published in the independently peer-reviewed medical literature, and it’s worth mentioning that the MHRA has already awarded several approvals, including their approval of the PIP and their approval of the MIA (both the PIP and MIA are relevant to the MAA for DCVax-L that is currently under review).

So, I would have to agree with you—the value of UK Specials Program and its data are significant and worthy of our attention!






https://thejns.org/caselessons/downloadpdf/view/journals/j-neurosurg-case-lessons/8/2/article-CASE24112.pdf

He is the biggest pumper on twitter on behalf of NWBO. Danish is a close 2nd.

How about that $80M revenue forecast for Specials in 2022?

When such folks start blaming everyone except the company management and that the world is conspiring against only one company in the world, there is a big problem.

No one stopped LP from applying to EU earlier in the year. No one stopped her from applying for UK reimbursement 6-9 months ago. No one is stopping LP from going to big biotech investor conferences and building awareness/credibility. They have had 4 years since data lock and over 2 years since TLD and JAMA to do so.

Victim mindset at its finest!

Agreed.

That's strange 
This PDF is in the NWBO vs concord case docket on courtlistener . Now I figured out , that it is an exhibit in NWBO case docket . So you are right , I think that's what confusion has been . It's not NWBO' pre trial conference , but document is in NWBO case docket as an exhibit . 
So back to waiting game 
Thanks for pointing out 

This is the header of the PDF you posted:

UNITED STATES DISTRICT COURT
SOUTHERN DISTRICT OF NEW YORK
PHUNWARE, INC.,
Plaintiff,
v.
UBS SECURITIES LLC,
Defendant.
23 Civ. 6426 (DEH)
OPINION AND ORDER
DALE E. HO, United States District Judge:

NWBO is referenced but this update is not about them.

zero82,

Why are you being so harsh? It’s not easy to predict future events with precision 😶


https://jamanetwork.com/journals/jamaoncology/fullarticle/2798847


LC has come around and is now advocating for the independent JAMA analysis to be featured on the main page of the company’s website!

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=175554294

https://x.com/sharpie510/status/1869496208542339183

https://x.com/sharpie510/status/1870209310934052882

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=175562433

https://investorshub.advfn.com/boards/replies.aspx?msg=175562433

Options?
1. Annex 2 for Direct testing/stufies, and/or
2. Annex 2 for Alternative made direct testing/studies, and/or
3. Annex 2 for Eden comparison, and/or testing/studies.
4. Annex 2 for Pediatric testing/studies. and/or
5. Annex 2 for Combo testing/studies, tumor response endpoint.

Here's what pathological lying looks like, btw.  

https://www.breitbart.com/the-media/2024/12/20/nolte-breitbarts-liar-year-2024-award-goes-joe-scarborough/

Wow, that Advent sure has some operation! 🙄
Nice job pretending to see nothing wrong with it, btw.  

LC,

You raise a valid point about the website: They really should align the main page with the updates from their press releases. ✅️

Thanks for refocusing our attention on the significant developments that have unfolded since the landmark P3 concluded …

They could also highlight the emerging combo data on the main page, and NWBO’s recent acquisition of another patent-fortified dendritic cell technology developed by the world-renowned New York research institution/hospital, Roswell Park.



https://jamanetwork.com/journals/jamaoncology/fullarticle/2798847

https://brownneurosurgery.com/breakthrough-brain-cancer-vaccine/

https://nwbio.com/audio-of-nwbio-2023-annual-shareholders-meeting/


https://www.nature.com/articles/s41467-024-48073-y


https://thejns.org/caselessons/downloadpdf/view/journals/j-neurosurg-case-lessons/8/2/article-CASE24112.pdf

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=175185151

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=175149927

From ChatGPT for whatever it is worth:

"Yes, it is not uncommon for a court to hold a pretrial conference before ruling on a Motion to Dismiss (MTD) in a civil case. However, the timing and purpose of the conference can vary depending on the court, the judge, and the procedural rules applicable to the case. Here’s some context:

You should be asking why is the GC pitching the company and not the CEO CFO? And, how can he spend so much time on the BBS but not make a simple correction to their website's homepage?

"NW Bio’s proprietary manufacturing technology enables the Company to produce its personalized vaccine in an efficient, cost-effective manner. The Company has a broad platform technology for DCVax dendritic cell-based vaccines. The Company’s lead product, DCVax-L, is currently in a 348-patient Phase III trial for patients with newly diagnosed Glioblastoma multiforme (GBM), the most aggressive and lethal brain cancer. The Company’s second product, DCVax-Direct, is currently in a 60-patient Phase I/II trial for direct injection into all types of inoperable solid tumor cancers. "

"Advent bio storage"...That's just rich.  😂

Plenty of legacy savvy shareholders out there. LOL

Remember, part of the MHRA "Process" is asking for more information. 

Droid,

Thanks for reposting that again 😶

I think you’re just throwing fud spaghetti at the wall over and over hoping something sticks...


https://nwbio.com/audio-of-nwbio-2023-annual-shareholders-meeting/

June 2024

https://www.prnewswire.com/news-releases/northwest-biotherapeutics-announces-exclusive-in-license-of-portfolio-of-dendritic-cell-technology-and-intellectual-property-302174237.html

February 2024

https://www.prnewswire.com/news-releases/northwest-biotherapeutics-moves-from-optimization-of-flaskworks-prototype-to-fabrication-of-gmp-compliant-units-for-installation-validation-and-final-testing-prior-to-regulatory-certification-302054769.html

December 2023

https://www.prnewswire.com/news-releases/northwest-biotherapeutics-announces-that-a-marketing-authorization-application-has-been-submitted-to-the-uk-mhra-for-dcvax-l-for-glioblastoma-302021038.html

September 2023

https://www.prnewswire.com/news-releases/northwest-biotherapeutics-announces-that-dr-linda-liau-has-joined-the-companys-scientific-advisory-board-301924864.html

March 2023

https://www.prnewswire.com/news-releases/northwest-biotherapeutics-and-advent-bioservices-announce-receipt-of-license-for-commercial-manufacturing-at-sawston-uk-facility-301776725.html

December 2022

https://www.prnewswire.com/news-releases/northwest-biotherapeutics-announces-mhra-approval-of-license-for-gmp-manufacturing-at-sawston-uk-facility-301449083.html

August 2022

https://www.prnewswire.com/news-releases/northwest-biotherapeutics-announces-approval-of-pediatric-investigation-plan-pip-by-mhra-301610850.html

July 2022

https://www.prnewswire.com/news-releases/northwest-biotherapeutics-announces-filing-of-application-for-license-for-commercial-manufacturing-at-sawston-uk-facility-301581737.html

February 2022

https://www.prnewswire.com/news-releases/northwest-biotherapeutics-announces-commencement-of-cancer-vaccine-production-at-its-sawston-uk-facility-301484857.html

September 2020

https://www.prnewswire.com/news-releases/northwest-biotherapeutics-acquires-flaskworks-301122058.html

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=175149927

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=175399357

Of course mute inept nonmanagement is no help with updates. Linda worthless has her head too far up her ass to speak or issue a pr.

Fair point . But that could have happened when they said inspections are scheduled and they could have canceled the inspections because they found issues and were going to issue more RFI or short staff etc . I would highly doubt it is anywhere close to common once the inspections are officially finished , they would send their inspectors back to the sites again. 

https://storage.courtlistener.com/recap/gov.uscourts.nysd.590344/gov.uscourts.nysd.590344.166.1.pdf

Really not sure , why pretrial conference is MTD is not denied already ?? May be a lawyer can comment if this is standard procedure ? 
Why waste time on pre trial conference if trial was not going to take place if they were going to grant MTD. 
Does this mean that MTD is denied or going to be denied?

Priceless: "Tic toc MF-ers".

Which means more than likely, the motion to dismiss will be DENIED!

😀.   That answers the question of you know who all, who harass the critics by saying , then why don't you sell and move on. 
Lol :)

This hits hard this year 😂

https://x.com/naiivememe/status/1870099208637952190

Gregory Zivic, MD
@metacollectiveG
·
3h
$NWBO When you think of health care, BP, Insurance, remember they’re not in it for you. People die for a lot of reasons, one of them should not be killing a life saving treatment that is actually affordable and could be available to everyone.

Gregory Zivic, MD
@metacollectiveG
·

Gregory Zivic, MD
@metacollectiveG
$NWBO
@adamfeuerstein
is the nerd who instead of wilting under the pressure developed a projection of ego based on nothing. The tongue is devoid of any punch, but as the bitch of bigger nerds he can’t grasp his insignificance. He’s a punk, a twit, a nothing. He has no protection

Ex,

You as the leader of the "gang", have you ever thought about contacting Mrs. Posner?
I think that your financial problems (why else would you earn your money here for 2 pence and a cent with gossip and lies) can be solved in one fell swoop and make a rich man of you, if you just sign up as a whistleblower.
A rich life ahead of you, right?
Think about this for a change.

Mani, if they announced that routine inspections were completed (for sake of argument assume the statement is made to the public in good faith), and lo...the company was incorrect because unexpectedly the MHRA returned for followup inspection work (for whatever reason)...

Now, what would be the reaction to that news? I can guess and it wouldn't be good.

Settlement?

Make no mistake about it, the Judge is trying not to step on toes until it is unavoidable.

I will be sure to remind the bag holders after UK approval when LP disappoints again! Don't blame it on shorts and market makers if she cant arrange non dilutive cash! ;)

LOL. Cabal soldiers come to defend their FUD narrative to sell on approval. So hilarious!
Holding for partnership/buyout announcement soon after approval will provide big returns.

LOL. You'll be long gone after approval. 👿☠️

Haha, what an idiot. Thats exactly the opposite of what will happen bagholder.

I will remind you in late Q1 2025 what a bag holder move that would turn out to be! ;)

Cabal soldiers and their bosses certainly want retail to sell on approval, but savvy investors will hold until at least partnership/buyout announcement for a much higher return.

You're right. These bashers probably have short positions on 100s of companies, yet they have all day to focus on NWBO. It just goes to show where these bashers see their greatest exposure for financial loss to be.

It is the inverse of what Retail Longs properly have identified in NWBO as being an asymmetric risk reward investment + booster engine being it also has the high potential for being a unicorn company.

I am assuming you’re directing that towards LP? Would fit the bill perfectly for all the lies, loss of money and time over the years.

Hey ... if you pumpers are so secure and confident in your investment , then why do you post . Spend that time somewhere else and enjoy life . Why bother reading and posting on message boards . Just put a limit sell order and forget about it . 

Oh let me guess then it must be your job 

Perfect logic 

Lol couldn't have expected any thing more than likes of you 

Yes, 3 million is correct at 10 doses per patient, or 300,000 patients, or to put it poorly, customers.

Lol
Typical reply just as stated in my post . 
Keep it up

If that's the case then why do all u bashers feel the need to post 10-20x a day telling us kings how worthless the company and stock is... 

Most rational people would find a better use of their time but u guys show up here every day to tell us ..

Almost like it's your job !!! 

U can set your watch by when u losers clock in each day 

Tic toc MF-ers

Investor082. Why are you wasting our time with your posts? To ignore you go.

Doc,

Thanks for the reply. 3m! Wow!

I'll be happy and gone with $1.50.

This is a non-rev biotech with 1.7B Shares authorized, and 1.3B plus share outstanding diluting daily to pay the Advent Bills.

And you are seriously trying to compare NWBO with Google who has 300B plus in annual revenue? GTFOOH Pumper with that BS argument. Do you know why Google splits? Because their share price goes up....SMFH. what is your point exactly pumper? Mine is this is a POS that dilutes daily and has no revenue and no path to revenue and 1.3B plus shares outstanding....understand now. NWBO has undergone multiple REVERSE SPLITS....because their share price tanks and has tanked since inception over 99.999% destruction in shareholder value. Unreal in the level of stupidity and BS from the pump crew.

What is your point - you aren't being clear.

As of December 20, 2024, Alphabet (Google) has 5.84 billion shares outstanding. The number of shares outstanding can change due to stock splits and buybacks.

Agree

As a reference, Phunware is down over 15% since the ruling couple of weeks ago. Regardless of when the MTD ruling comes it will pretty much be a nothing burger. Nothing will move the stock expect $100-200M in non dilutive funding from big pharma (minus a momentary spike at UK approval). Otherwise, the stock will continue to trade down given the ongoing dilution.